Biosynthesizing Forskolin via Engineered P450 Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing forskolin and related compounds are limited, relying on purification from Coleus forskohlii or chemical synthesis, which may not be efficient or scalable.
Innovation Solution
Development of novel biosynthetic methods involving host organisms engineered with heterologous nucleic acids encoding specific enzymes to catalyze hydroxylation and oxidation reactions at specific positions of 13R-manoyl oxide, allowing for the production of oxidized 13R-MO and ultimately forskolin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If forskolin is purified from Coleus forskohlii or produced chemically, then forskolin can be obtained, but the production efficiency and scalability are limited
Solution Approach 1:
The patent employs host organisms (bacteria, yeast, or plant cells) that are engineered to autonomously produce forskolin and related compounds through introduced heterologous nucleic acids encoding specific enzymes. The biological system serves itself by utilizing its metabolic machinery to synthesize the target compounds, eliminating the need for complex external chemical synthesis procedures and enabling scalable production through simple cultivation.
Solution Approach 2:
The patent uses heterologous nucleic acids and expressed enzymes as intermediaries to transfer the biosynthetic capability from source organisms to host organisms. These intermediaries (plasmids, viral vectors, or other delivery vehicles carrying foreign genes) mediate the introduction of key enzymes into the host, enabling the host to perform functions it would not naturally execute, thereby achieving efficient forskolin production.
2Manufacturing precision
If region- and stereospecific oxidation of five carbon positions is performed to produce forskolin from 13R-MO, then the desired compound is obtained, but the process becomes complex and difficult to scale
Solution Approach 1:
The patent replaces complex chemical oxidation mechanisms with biological enzymatic oxidation systems. Instead of using multiple chemical reagents and harsh conditions to achieve region- and stereospecific oxidation, the invention introduces heterologous enzymes that naturally perform these specific oxidations as part of their catalytic function, thereby achieving high precision with simpler, more controllable biological processes.
Solution Approach 2:
The patent changes the fundamental parameters of the oxidation process by transitioning from chemical to biological catalysis. This involves altering the catalyst type (from chemical reagents to enzymes), reaction conditions (from harsh chemical environments to mild physiological conditions), and mechanism (from non-specific chemical reactions to highly specific enzymatic transformations), thereby achieving the desired stereospecificity with reduced process complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables efficient and scalable biosynthesis of forskolin and its oxidized variants, potentially offering improved pharmaceutical applications and production efficiency.
Implementation Method 1
A heterologous nucleic acid encoding an enzyme capable of catalysing hydroxylation of 13R-manoyl oxide (13R-MO) and/or an oxidised 13R-MO derivative at the 11 position
Implementation Method 2
catalysing oxidation of the hydroxyl group to form an oxo-group at the 11 position of 11-hydroxyl-13R-MO
Implementation Method 3
A heterologous nucleic acid encoding an enzyme capable of catalysing hydroxylation of 13R-MO and/or oxidised 13R-MO at the 1 position
Implementation Method 4
A heterologous nucleic acid encoding an enzyme capable of catalysing transfer of an acyl group to an —OH of a hydroxylated 13R-MO
Data Source
AI summary
The invention described materials and methods for producing oxidized 13R-MO, such as forskolin. In particular, the invention describes P450s involved in oxidation of 13R-MO including CYP76AH8, CYP76AH11, CYP76AH15, CYP76AH17, CYP71D381 and CYP76AH9. Host organisms expressing one or more of these P450s are useful in the production of oxidized 13R-MO.